Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Baxter Healthcare Corporation

US Class II Ongoing · initiated 2025-08-20

Discoloration

Northwind Pharmaceuticals LLC

US Class II Ongoing · initiated 2025-08-20

Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected…

Lannett Company Inc.

US Class II Completed · initiated 2025-08-19

Presence of Foreign Tablet/Capsule: Two (2) bottles labeled as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Su…

Medline Industries, LP

US Class III Ongoing · initiated 2025-08-19

Subpotent drug

B BRAUN MEDICAL INC

US Class I Ongoing · initiated 2025-08-18

Presence of Particulate Matter.

Amneal Pharmaceuticals, LLC

US Class II Ongoing · initiated 2025-08-18

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro…

Amneal Pharmaceuticals, LLC

US Class II Ongoing · initiated 2025-08-18

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro…

Amneal Pharmaceuticals, LLC

US Class II Ongoing · initiated 2025-08-18

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro…

Amneal Pharmaceuticals, LLC

US Class II Ongoing · initiated 2025-08-18

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro…

Amneal Pharmaceuticals, LLC

US Class II Ongoing · initiated 2025-08-18

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro…

B BRAUN MEDICAL INC

US Class I Ongoing · initiated 2025-08-18

Presence of Particulate Matter

Wellness by London Drugs Hand Sanitizer Gel

Canada Type III Ongoing · initiated 2025-08-15

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Sandoz Inc

US Class II Ongoing · initiated 2025-08-13

Temperature Abuse

Jamp Bisoprolol 5 mg tablet

Canada Type II Ongoing · initiated 2025-08-13

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

VIONA PHARMACEUTICALS INC

US Class II Ongoing · initiated 2025-08-12

Discoloration

Lannett Company Inc.

US Class II Terminated · initiated 2025-08-11

Labeling: Label Mix-up. A bottle labeled as Lisdexamphetamine Dimesylate Capsules 40mg, contained Lisdexamphetamine Dimesylate Capsules 30mg.

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-08-08

Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf…

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-08-08

CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-08-07

CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-08-07

CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-08-07

CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.

YF-Vax powder for solution

Canada Type II Ongoing · initiated 2025-08-07

Packaging. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-08-06

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-08-06

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm

Westminster Pharmaceuticals LLC

US Class II Ongoing · initiated 2025-08-06

CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.